Phillips et al v. Encompass Health Corporation et al

On October 3, 2018, a securities fraud class action was initiated in the United States District Court for the Northern District of Alabama by lead plaintiff Dennis Phillips against Encompass Health Corporation, its CEO Mark J. Tarr, and CFO Douglas E. Coltharp. The complaint alleged that between April 4, 2017 and November 7, 2018, the defendants made materially false and misleading statements regarding the company's business and compliance. Specifically, Encompass Health failed to disclose that its revenue growth was allegedly fueled by illicit physician referral arrangements that violated the Anti-Kickback Statute and False Claims Act. The company also concealed a pending Department of Justice investigation into its referral practices. When the investigation was publicly revealed in 2019, Encompass Health's stock price declined sharply, causing significant losses to investors.

The U.S. District Court for the Northern District of Alabama dismissed the amended complaint with prejudice, ruling that the plaintiffs failed to adequately plead a strong inference of scienter as required by the Private Securities Litigation Reform Act. The dismissal was subsequently affirmed by the U.S. Court of Appeals for the Eleventh Circuit.

The central legal dispute was whether Encompass Health and its executives knowingly misled investors by attributing financial success to legitimate business drivers while concealing widespread violations of healthcare fraud and abuse laws, as well as a related federal investigation, and whether such omissions rendered their public statements materially false and artificially inflated the company's stock price.

The ruling reinforced the stringent pleading standards for scienter in securities fraud cases, particularly those relying on confidential witnesses and subsequent government investigations. It served as a cautionary tale for post-acute healthcare providers, highlighting the severe securities law consequences of undisclosed compliance risks. The case underscored the critical importance for publicly traded healthcare companies to maintain robust internal controls and transparent disclosures regarding physician relationships and billing practices.